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Abstract
Common polymorphisms of the Cholestryl Ester Transfer Protein (CETP) gene may predict lower risk of cognitive decline. We
investigated the association of cognitive function with CETP genotype in a population-based cohort of 4135 persons aged 35–82 years.
ognitive function was measured with the Ruff Figural Fluency Test (RFFT; worst score, 0 points; best score, 175 points) and CETP I405V
nd Taq1B genotypes were determined by polymerase chain reaction. RFFT score was not associated with I405V genotype in persons aged
5–64 years. Remarkably, beyond age 65, homozygous valine carriers had higher RFFT scores than heterozygous carriers and noncarriers:
FFT (SD), 52 (21), 49 (18), and 47 (17) points, respectively (p  0.005). There also was a statistically significant interaction between
405V genotype and age. Beyond age 65, the difference between homozygous valine carriers and noncarriers increased by 0.11 point per
ear (p  0.005). RFFT score was not associated with Taq1B genotype. In conclusion, CETP I405V valine homozygosity was associated
ith better cognitive function in persons aged 65 years or older.
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It is well established that the risk of Alzheimer disease is
dependent on APOE genotype (Bertram et al., 2007). How-
ever, there probably are several other genes that increase the
susceptibility for Alzheimer disease, and recently, it was
suggested that the risk of dementia and Alzheimer disease is
also dependent on Cholesteryl Ester Transfer Protein
(CETP) genotype (Sanders et al., 2010).
CETP facilitates the transfer of cholesteryl esters and
riglycerides between different types of lipoproteins in
* Corresponding author at: University Center for Geriatric Medicine,
Internal Postcode AA43, University Medical Center Groningen, PO Box
30001, 9700 RB Groningen, the Netherlands. Tel.: 31 50 361 39 21; fax:
31 50 361 90 69.HE-mail address: g.j.izaks@umcg.nl (G.J. Izaks).
0197-4580 © 2012 Elsevier Inc.
10.1016/j.neurobiolaging.2012.02.022
Open access under the Elsevier OA license.plasma (Hamilton and Deckelbaum, 2007), and some vari-
ations in CETP are linked to higher levels of high density
lipoprotein (HDL) cholesterol (Thompson et al., 2008). Ac-
cordingly, these variations in CETP may predict a lower
ncidence of cardiovascular disease (Prospective Studies
ollaboration et al., 2007; Thompson et al., 2008). CETP
ay also play a role in dementia as it is increasingly
ecognized that cardiovascular disease and dementia
hare several common risk factors. Hypertension, diabe-
es mellitus, dyslipidemia, and obesity, for example, have
ll been linked to an increased risk of Alzheimer disease
Gustafson et al., 2003; Kivipelto et al., 2005; Luchsinger
t al., 2005; Whitmer et al., 2005). Equally important,
hese cardiovascular risk factors have been associated
ith cognitive decline in persons without dementia (van
en Berg et al., 2009). Thus, if variations in CETP predict
DL cholesterol and cardiovascular risk, CETP genotype
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ment in general.
The aim of this study was to investigate the association of
common variations in CETP genotype with cognitive function
n a large sample from the general population. Cognitive tests
nd CETP genotyping were performed in a population-based
ohort of 4135 persons aged 35 to 82 years.
. Methods
.1. Study population
The study population comprised all participants of the third
urvey of the Prevention of Renal and Vascular ENd-stage
isease study (PREVEND) that is being conducted in the city
f Groningen, the Netherlands (n  5862). PREVEND was
esigned to investigate prospectively the natural course of
micro)albuminuria and its relation to renal and cardiovascular
isease in the general population. Details of the study protocol
ave been published elsewhere (Lambers Heerspink et al.,
008; Mahmoodi et al., 2009).
The PREVEND study has been approved by the Medical
thical Committee (METc) of the University Medical Cen-
er Groningen, Groningen, the Netherlands, and is con-
ucted in accordance with the guidelines of the Declaration
f Helsinki. All participants gave written informed consent.
.2. Cognitive function
Cognitive function was measured with the Ruff Figural
luency Test (RFFT) (Ruff, 1996; Ruff et al., 1987). The
FFT is a measure of nonverbal fluency. Fluency is gener-
lly seen as an executive function and is sensitive to early
ognitive dysfunction (Twamley et al., 2006). The RFFT
equires the participants to draw as many designs as possi-
le within a set time limit while avoiding repetitions of
esigns (Ruff, 1996; Ruff et al., 1987). In contrast to many
ther neuropsychological tests, the RFFT is sensitive to
hanges in executive function in both young and older
ersons (Izaks et al., 2011; Ruff et al., 1987). The main
utcome measure of the RFFT is the total number of unique
esigns, which varies from 0 points (worst score) to 175
oints (best score). Each RFFT was analyzed by 2 indepen-
ent examiners according to strict scoring rules (intraclass
orrelation coefficient, 1.00; 95% confidence interval [CI],
.99–1.00) (Izaks et al., 2011; Ruff, 1996).
.3. Age and educational level
Age was defined as the age in full years on the date of
erformance on the RFFT. Educational level was divided into
groups according to the International Standard Classification
f Education (ISCED) (United Nations Educational, Scientific
nd Cultural Organization, 2006): primary school, ISCED 0 to
(0–8 years of education); lower secondary education,
SCED 2 (9–12 years of education); higher secondary educa-
ion, ISCED 3–4 (13–15 years of education); university,
SCED 5 (16 or more years of education). a.4. Genotyping
Genotyping was performed at the University Medical
enter Groningen, Groningen, the Netherlands. DNA was
xtracted from whole blood using the QIAamp mini kit
Qiagen, Hilden, Germany). The CETP I405V (rs5882) and
aq1B (rs708272) single-nucleotide polymorphisms were
nalyzed using TaqMan-MGB probes and primers, de-
igned through the Assay-by-Design service of Applied
iosystems (Applied Biosystems, Applera Nederland,
ieuwerkerk aan de IJssel, the Netherlands) (Borggreve et
l., 2005). Assays were carried out according to the manu-
acturer’s recommendations on an ABI 7900HT apparatus
Applied Biosystems).
APOE genotype (rs429358 and rs7412) was also deter-
ined. This was done by allelic discrimination on a Taq-
an 7500 Real Time PCR system, using the single-nucle-
tide polymorphism genotyping mixes C-3084793-20 and
-904973-10 and TaqMan Universal PCR Master Mix No
mpErase (Applied Biosystems). The method has been
alidated against a previously described restriction isotyp-
ng procedure (Blaauwwiekel et al., 1998; Reymer et al.,
995).
.5. Other measurements
The main cardiovascular risk factors were measured be-
ause they may be associated with CETP genotype as well
s with cognitive function. Diabetes mellitus was defined as
ither a fasting glucose equal to or greater than 7.0 mmol/L,
r a nonfasting glucose equal to or greater than 11.1
mol/L, or the use of glucose-lowering drugs (World
ealth Organization, 1999). Smoking was defined as cur-
ent smoking or cessation of smoking less than 1 year before
he study. Blood pressure was automatically measured in
upine position during 10 minutes (Dinamap monitor, John-
on & Johnson Medical, Inc., Tampa, FL, USA), and re-
orted as the mean of the last 2 recordings. Plasma glucose
nd total cholesterol were measured by dry chemistry (East-
an Kodak, Rochester, NY, USA). HDL cholesterol was
easured with a homogeneous method (direct HDL, Aero-
et TM System, Abbott Laboratories, Abbott Park, IL,
SA). Non-HDL cholesterol was calculated as total choles-
erol minus HDL cholesterol. Albuminuria was determined
n 2 consecutive 24-hour urine samples by nephelometry
Dade Behring Diagnostic, Marburg, Germany). Elevated
lbuminuria was defined as an average urinary albumin
xcretion equal to or greater than 30 mg per 24 hours. Data
n disease history were derived from a questionnaire at
nclusion, and from the Dutch national registries of hospital
ischarge diagnoses and death certificates during follow-up.
ata on drug use were obtained from the InterAction Da-
aBase (www.iadb.nl) which comprises pharmacy-dispens-
ng data of the pharmacists in the study region (Monster et
l., 2002).
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Differences in numerical variables were tested with the
independent-samples t test or, if appropriate, 1-way analysis
f variance (ANOVA). Differences in categorical variables
ere tested by 2 test or by Fisher exact test where appro-
priate.
The association between RFFT score, age, and CETP
polymorphisms was analyzed by linear regression analysis.
The regression model also included the variables gender,
educational level, diabetes mellitus, smoking status, body
mass index (BMI), systolic blood pressure, glucose, HDL
cholesterol, non-HDL cholesterol, elevated albuminuria,
history of coronary heart disease, history of cerebrovascular
disease, use of blood pressure-lowering agents, use of lipid-
lowering agents, and APOE 4 carriership. For the associ-
ation between RFFT score and CETP I405V genotype, the
regression model also included the interaction terms Age 
65 years  Ile/Val  Age and Age  65 years  Val/Val 
ge. The interaction terms were added to the model after
nitial inspection of the raw data. In all regression models,
he variables age, body mass index, systolic blood pressure,
lucose, HDL cholesterol, and non-HDL cholesterol were
ntered as continuous variables. All other variables were
ntered as categorical variables.
To adjust for multiple comparison, differences between
roups were considered statistically significant if p  0.005
adjusted for multiple comparisons). Regression coefficients
ere considered statistically significant if p  0.05. Statis-
ical analysis was done with SPSS 16.0 for Windows (SPSS,
nc., Chicago, IL, USA).
.7. Additional analysis
As a consequence of its design, the total PREVEND
ohort comprised a relatively high number of persons with
levated albuminuria. Because this may influence some data
nalyses, all analyses were repeated in a representative
ample of the Groningen population. This so-called Gro-
ingen Random Sample included 2404 persons.
.8. Systematic review
Finally, we performed a systematic review of the litera-
ure to compare our findings with other studies. The search
trategy and selection of the studies are detailed in the
upplementary file.
. Results
.1. Study population
A total of 4158 persons (71%) performed the RFFT. The
FFT scores of the other 1704 persons (29%) were missing:
271 persons (22%) refused to perform the RFFT, and 434
ersons (7%) had missing RFFT scores for other reasons. In
ddition, 20 persons (0.5%) who performed the RFFT were
xcluded because the data on educational level were miss- bng. Three persons (0.1%) were excluded because they were
ounger than 35 years and their number was too small to
orm a separate age group. Thus, the total study population
ncluded 4135 persons (Table 1). Information on CETP
405V genotype was available for 3986 persons (96%), and
n CETP Taq1B genotype for 4000 persons (97%).
The persons who performed the RFFT were slightly
ounger than the persons with missing RFFT scores (mean
ge [SD], 55 [12] vs. 56 [12] years; p  0.001), and
ncluded fewer women (48% vs. 53%; p  0.001). The
ersons who performed the RFFT also had higher educa-
ional levels (p  0.001; data not shown). There was no
ifference in the distribution of CETP genotypes.
.2. CETP I405V and RFFT score
The distribution of the CETP I405V genotypes was in
ardy-Weinberg equilibrium (p  0.99). There were no
ifferences in age, gender, or educational level between
ersons with different CETP I405V genotypes. As ex-
ected, homozygous valine carriers had higher levels of
DL cholesterol than heterozygous valine carriers and non-
arriers (Table 2). There were no statistically significant
ifferences in other cardiovascular risk factors or APOE 4
arriership.
Overall, there was no difference in mean RFFT score
Table 1
Characteristics of study population
Characteristic Value
n (%) 4135 (100)
Gender, n (%)
Female 1978 (48)
Male 2157 (52)
Ethnicity, n (%)
Western European 3963 (96)
Other 172 (4)
Age, mean (SD), y 55 (12)
Age, n (%), y
35–44 920 (22)
45–54 1277 (31)
55–64 1002 (24)
65–74 691 (17)
 75 245 (6)
Educational level, n (%)
Primary school 406 (10)
Lower secondary education 1225 (29)
Higher secondary education 1108 (27)
University 1396 (34)
CETP I405V genotype, n (%)
All 3986 (96)
Ile/Ile 1876 (45)
Ile/Val 1699 (41)
Val/Val 411 (10)
CETP Taq1B genotype, n (%)
All 4000 (97)
B1/B1 1347 (33)
B1/B2 1881 (45)
B2/B2 772 (19)
RFFT score, mean (SD) 69 (26)
Key: Ile, isoleucine; RFFT, Ruff Figural Fluency Test; Val, valine.etween the 3 CETP I405V genotypes (Table 2). However,
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appeared that the association of CETP I405V genotype with
FFT score was dependent on age (Fig. 1). Up to the age of
4 years, there was no difference in RFFT score between
ersons with different CETP I405V genotypes but in per-
ons aged 65 years or older, homozygous valine carriers had
igher (better) RFFT scores than heterozygous valine car-
iers and the noncarriers. Accordingly, the unadjusted mean
FFT score (SD) in persons aged 65 or older was 52 (21)
oints for homozygous valine carriers, 49 (18) points for
eterozygous valine carriers, and 47 (17) points for noncar-
iers (p  0.005).
The difference between persons younger than 65 years
and persons aged 65 years or older was confirmed in mul-
Table 2
RFFT score, demographic characteristics and main cardiovascular risk fac
CETP I405V genotype
Ile/Ile Ile/Val Va
n 1876 1699 411
RFFT score, mean (SD) 69 (26) 69 (26) 6
Women, n (%) 903 (48) 811 (48) 20
Age, mean (SD), y 55 (12) 55 (12) 5
Educational level, n (%)
Primary school 168 (9) 183 (11) 3
Lower secondary education 542 (29) 501 (29) 12
Higher secondary education 513 (27) 453 (27) 10
University 653 (35) 562 (33) 13
Cardiovascular risk factors
Diabetes mellitus, n (%) 119 (6) 103 (6) 2
Current smoker, n (%)b 429 (23) 420 (25) 9
Body mass index, mean (SD) 27 (4) 27 (4) 2
Systolic blood pressure, mean
(SD), mm Hg
126 (18) 126 (18) 12
Glucose, mean (SD), mmol/L 4.9 (1.0) 4.9 (1.0) 4.
Total cholesterol, mean (SD),
mmol/Lc
5.35 (1.08) 5.37 (1.04) 5.4
HDL cholesterol, mean (SD),
mmol/Lc
1.39 (0.38) 1.42 (0.38) 1.4
Non-HDL cholesterol, mean
(SD), mmol/Lc
3.96 (1.05) 3.95 (1.01) 3.9
Elevated albuminuria, n (%)b 273 (15) 237 (14) 6
History, n (%)
Coronary heart disease 65 (3.5) 82 (4.8) 1
Cerebrovascular disease 16 (0.9) 14 (0.8)
Current medication, n (%)b
Blood pressure-lowering agents 427 (30) 369 (29) 9
Lipid-lowering agents 255 (18) 238 (19) 5
APOE 4 carrier, n (%)d 546 (30)e 502 (30)e 11
Body mass index calculated as weight (kg)/height (m2).
ey: HDL, high-density lipoprotein; Ile, isoleucine; RFFT, Ruff Figural F
a Sum of the percentages is not equal to 100 due to rounding.
b Different total number due to missing data. For the genotypes Ile/Ile, Il
persons, respectively; data on albuminuria were complete for 1860, 16
1410, 1285, and 325 persons, respectively. For the genotypes B1/B1, B
persons, respectively; data on albuminuria were complete for 1330, 18
1052, 1427, and 592 persons, respectively.
c To convert from mmol/L to mg/dL, multiply mmol/L by 39.
d APOE genotypes, 2/4, 3/4, and 4/4.
e Different total number due to missing data: ntotal  3853.
f Different total number due to missing data: ntotal  3860.tiple linear regression analysis (Table 3). In the fully ad- ajusted model, the RFFT score of the total number of ho-
mozygous valine carriers was 2.83 points lower than the
RFFT score of noncarriers (95% CI, 5.77 to 0.11; p 
.06). However, in persons aged 65 years or older (n 
00), there was a statistically significant interaction between
aline homozygosity and age. Beyond age 65, homozygous
aline carriers had higher RFFT scores than noncarriers and
he difference in RFFT score increased by 0.11 point per
ear of age (95% CI, 0.03–0.19; p  0.005), after adjusting
or age, educational level, cardiovascular risk factors, and
POE 4 carriership (Table 3). Using the full regression
odel, it was estimated that compared with the RFFT score
f noncarriers, the RFFT score of homozygous valine car-
iers was 4.38 points higher at age 65, 5.49 points higher at
pendent on CETP genotype
CETP Taq1B genotype
p B1/B1 B1/B2 B2/B2 p
1347 1881 772
0.71 69 (26) 69 (26) 68 (26) 0.63
0.77 636 (47) 902 (48) 381 (49) 0.64
0.84 54 (12) 55 (12) 55 (11) 0.41
127 (9)a 184 (10)a 83 (11)a
0.55 406 (30) 537 (29) 231 (30) 0.62
378 (28) 502 (27) 198 (26)
436 (32) 658 (35) 260 (34)
0.80 88 (7) 103 (6) 53 (7) 0.29
0.36 307 (23) 446 (24) 190 (25) 0.56
0.82 27 (4) 27 (4) 27 (5) 0.55
0.52 126 (17) 126 (18) 126 (18) 0.77
0.74 4.9 (1.0) 4.9 (0.9) 4.9 (0.9) 0.34
0.16 5.34 (1.08) 5.39 (1.04) 5.37 (1.05) 0.35
 0.001 1.37 (0.37) 1.41 (0.39) 1.47 (0.39)  0.001
0.75 3.97 (1.06) 3.98 (1.00) 3.90 (1.03) 0.17
0.72 208 (16) 258 (14) 108 (14) 0.33
0.08 52 (4.0) 76 (4.0) 31 (4.0) 0.99
0.45 14 (1.0) 13 (1.7) 9 (1.2) 0.40
0.66 290 (28) 427 (30) 187 (32) 0.37
0.96 191 (19) 253 (18) 114 (19) 0.69
0.89 395 (30)f 550 (30)f 221 (30)f 0.98
Test; Val, valine.
d Val/Val, data on smoking status were complete for 1867, 1689, and 407
410 persons, respectively; data on current medication were complete for
nd B2/B2, data on smoking status were complete for 1343, 1871, and 763
767 persons, respectively; data on current medication were complete fortors de
l/Val
8 (26)
4 (50)
5 (12)
9 (10)
9 (31)
8 (26)
5 (33)
3 (6)
2 (23)
7 (5)
5 (17)
8 (0.9)
6 (1.05)
7 (0.39)
9 (1.02)
4 (16)
3 (3.2)
6 (1.5)
8 (30)
9 (18)
6 (29)e
luency
e/Val an
80, and
1/B2 a
67, andge 75, and 6.60 points higher at age 85.
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o
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The distribution of the CETP Taq1B genotypes was also
in Hardy-Weinberg equilibrium (p 0.99). There was mod-
rate linkage disequilibrium between the TaqIB and I405V
olymorphisms (D’ 0.55). RFFT score was not dependent
n CETP Taq1B genotype and in all age groups, homozy-
gous B2 carriers had similar RFFT scores as heterozygous
Fig. 1. Mean Ruff Figural Fluency Test (RFFT) score dependent on CETP
nterval of ten-year age groups. Abbreviations: Ile, isoleucine; Val, valine
able 3
ultiple linear regression analysis of RFFT score on CETP I405V genoty
Model 1a Mode
B SE (B)  p B
Age, y 0.96 0.04 0.43  0.001 0.93
Gender
Male d d
Female 0.18 0.66 0.003 0.79 0.62
Genotype
Ile/Ile d d
Ile/Val 0.58 0.77 0.001 0.45 0.70
Val/Val 1.77 1.26 0.02 0.16 1.86
Age  65 y 
Ile/Val  age
0.02 0.02 0.01 0.43 0.01
Age  65 y 
Val/Val  age
0.11 0.04 0.04 0.003 0.10
Key: , standardized coefficient; B, unstandardized coefficient; HDL, high-
a Adjusted for educational level; adjusted R2 and residual standard devi
b Adjusted for the covariates in Model 1 plus diabetes mellitus, current sm
non-HDL cholesterol, and elevated albuminuria; adjusted R2 and resid
c Adjusted for the covariates in Model 2 plus history of coronary heart d
agents, current use of lipid-lowering agents, and APOE 4 carriership
d Reference category.B2 carriers and noncarriers (Fig. 1). There were no differ-
ences in age, gender, or educational level between the CETP
Taq1B genotypes but like homozygous I405V valine carri-
ers, homozygous Taq1B B2 carriers had higher HDL cho-
lesterol levels (Table 2). However, there were no differ-
ences in other cardiovascular risk factors or APOE 4
carriership. CETP Taq1B genotype was not associated with
ype and age. For clarity, data are presented as mean and 95% confidence
3986)
Model 3c
(B)  p B SE (B)  p
4 0.41  0.001 0.91 0.05 0.41  0.001
d
6 0.01 0.42 0.48 0.88 0.009 0.58
d
8 0.01 0.37 1.13 0.92 0.02 0.22
8 0.02 0.15 2.83 1.47 0.03 0.06
2 0.01 0.52 0.01 0.02 0.01 0.69
4 0.04 0.005 0.11 0.04 0.05 0.005
lipoprotein; Ile, isoleucine; RFFT, Ruff Figural Fluency Test; Val, valine.
.37 and 21, respectively.
tatus, body mass index, systolic blood pressure, glucose, HDL cholesterol,
dard deviation, 0.38 and 21, respectively.
history of cerebrovascular disease, current use of blood pressure-lowering
ed R2 and residual standard deviation, 0.38 and 20, respectively.genotpe (n 
l 2b
SE
0.0
0.7
0.7
1.2
0.0
0.0
density
ation, 0
oking s
ual stan
isease,
; adjust
A
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justing for various demographic characteristics, cardiovas-
cular risk factors, and APOE 4 carriership (Table 4).
3.4. Additional analysis
Essentially similar results were found if the analyses
were limited to the persons recruited from the Groningen
Random Sample that is representative of the Groningen
general population. Unadjusted, the mean RFFT score (SD)
in persons aged 65 or older was 56 (24) points for homozy-
gous valine carriers, 51 (18) points for heterozygous valine
carriers, and 47 (16) points for noncarriers (p  0.02). In
multiple linear regression analysis (fully adjusted model),
the RFFT score of the total number of homozygous valine
carriers was 6.72 points lower than the RFFT score of
noncarriers (95% CI, 11.29 to 2.14; p  0.004). How-
ever, beyond age 65, homozygous valine carriers had higher
RFFT scores than noncarriers and the difference in RFFT
score increased by 0.18 point per year of age (95% CI,
0.06–0.30; p  0.002). Compared with noncarriers, the
predicted RFFT score of homozygous valine carriers was
4.86 points higher at age 65, 6.64 points higher at age 75,
and 8.42 points higher at age 85 (fully adjusted model).
3.5. Systematic review
Thirteen studies were included in the systematic review.
Of these, 5 studies comprised data on CETP genotype and
cognitive function (Table 5), and 11 comprised data on
CETP genotype and dementia (Table 6). Most studies were
case-control studies but 3 studies were prospective cohort
studies (Reynolds et al., 2011; Sanders et al., 2010; Yu et
al., 2012). However, 1 prospective cohort study was rela-
tively small with short follow-up (Sanders et al., 2010), and
1 prospective cohort study was limited to a highly selected
Table 4
Multiple linear regression analysis of RFFT score on CETP Taq1B genot
Model 1a Model 2b
B SE (B)  p B S
ge, y 0.92 0.03 0.41  0.001 0.89 0
ender
Male d d
Female 0.29 0.66 0.006 0.66 0.50 0
Genotype
B1/B1 d d
B1/B2 0.01 0.74 0.001 0.99 0.22 0
B2/B2 0.23 0.94 0.003 0.82 0.26 0
Key: , standardized coefficient; B, unstandardized coefficient; HDL, hig
Figural Fluency Test; Val, valine.
a Adjusted for educational level; adjusted R2 and residual standard devi
b Adjusted for the covariates in Model 1 plus diabetes mellitus, current sm
non-HDL cholesterol, and elevated albuminuria; adjusted R2 and resid
c Adjusted for the covariates in Model 2 plus history of coronary heart d
agents, current use of lipid-lowering agents, and APOE 4 carriership
d Reference category.study population (Yu et al., 2012). The mean age of theparticipants was high. Thus, the level of evidence of the
studies was low and their generalizability limited.
Most studies yielded negative results. A few studies
found an association for the CETP I405V polymorphism but
the results of these studies were contradictory. Overall, the
findings on an association of CETP genotype with cognitive
function or the risk of dementia were equivocal.
4. Discussion
In this study, homozygous CETP I405V valine carriers
aged 65 years or older had better cognitive function than
heterozygous valine carriers and noncarriers. The difference
between homozygous valine carriers and heterozygous car-
riers and noncarriers was small but increased with increas-
ing age. Surprisingly, there was no association of CETP
I405V genotype with cognitive function in younger age
groups. By contrast, it appeared that CETP Taq1B genotype
was not associated with cognitive function in any age group.
The CETP I405V genotype is the most investigated
CETP genotype if it comes to the association of CETP
genotype with cognitive function. Several studies reported
on the association of the I405V valine genotype with the
risk of Alzheimer disease or age-related cognitive decline
(Arias-Vásquez et al., 2007; Barzilai et al., 2006; Chen et
al., 2008; Qureischie et al., 2008; Reynolds et al., 2011;
Rodríguez et al., 2006; Yu et al., 2012). Up until now,
however, their findings have been divergent. Although,
I405V valine carriers and noncarriers had a similar risk of
Alzheimer disease in most studies, 1 study showed that
homozygous valine carriers had an increased risk of Alz-
heimer disease (Arias-Vásquez et al., 2007). Because most
studies had a cross-sectional design and included a rela-
tively small number of persons, the equivocal findings may
be due to methodological differences. Our findings sug-
 4000)
Model 3c
 p B SE (B)  p
0.40  0.001 0.87 0.04 0.39  0.001
d
0.01 0.51 0.44 0.89 0.009 0.62
d
0.004 0.77 0.13 0.87 0.002 0.88
0.004 0.78 0.36 1.10 0.005 0.75
ity lipoprotein; Ile, isoleucine; SE (B), standard error of B; RFFT, Ruff
.37 and 21, respectively.
tatus, body mass index, systolic blood pressure, glucose, HDL cholesterol,
dard deviation, 0.37 and 21, respectively.
history of cerebrovascular disease, current use of blood pressure-lowering
ed R2 and residual standard deviation, 0.38 and 20, respectively.ype (n
E (B)
.04
.76
.76
.96
h-dens
ation, 0
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; adjustgested that homozygous CETP I405V valine carriers had
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d
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riers and noncarriers after the age of 65 years. This con-
curred with the findings of a recently published, prospective
study on CETP genotype and cognitive function (Sanders et
al., 2010). In this study, it was found that homozygous
valine carriers had lower risk of both Alzheimer disease and
memory decline. However, another prospective population-
based study that was published even more recently, did not
find an association of CETP genotype with cognitive func-
ion (Reynolds et al., 2011). In contrast to this report, our
tudy included young as well as older persons and used the
FFT as outcome measure. As performance on the RFFT
tarts to decline at a relatively young age (Izaks et al., 2011),
t is likely that the RFFT is more sensitive to cognitive
Table 5
Systematic review of studies on the association of CETP genotype with c
Outcome/Reference CETP
polymorphism
Design Mean
age, y
Mal
Global cognition
Barzilai et al.
(2006)
I405V Case-control 99 24, 2
Johnson et al.
(2007)
I405V Case-control 79 42
Yu et al. (2012) I405V Cohort 78 30
Declarative memory
Johnson et al.
(2007)
I405V Cross-sectional 79 42
Sanders et al.
(2010)
I405V Cohort 78f 49
Reynolds et al.
(2011)
I405V Cohort 74f 42
C-629A
Yu et al. (2012) I405V Cohort 78 30
Working memory
Sanders et al.
(2010)
I405V Cohort 78f 49
Reynolds et al.
(2011)
I405V Cohort 74f 42
C-629A
Yu et al. (2012) I405V Cohort 78 30
Processing speed
Sanders et al.
(2010)
I405V Cohort 78f 49
Reynolds et al.
(2011)
I405V Cohort 74f 42
C-629A
Yu et al. (2012) I405V Cohort 78 30
Executive function
Johnson et al.
(2007)
I405V Cross-sectional 79 42
Key: Val, valine.
a A detailed description of the search strategy and selection of the stud
polymorphisms and used several cognitive domains as outcome measu
outcomes.
b Reported separately for cases and controls.
c Not applicable.
d Ashkenazi Jews.
e Catholic nuns and priests.
f Median age.ecline in an early phase than other tests.The mechanism by which CETP I405V valine genotype
is associated with better cognitive function remains to be
elucidated. As the I405V valine genotype is associated with
higher HDL cholesterol levels, it is often assumed that it is
associated with lower cardiovascular risk (Thompson et al.,
2008), and thereby with lower risk of cognitive decline.
Indeed, several studies have found that high levels of HDL
cholesterol are protective against Alzheimer disease and
cognitive decline (Raffaitin et al., 2011; Reitz et al., 2010;
Singh-Manoux et al., 2008; van Exel et al., 2002). An
HDL-dependent mechanism could also explain why the
association of I405V valine with cognitive function was
only found in persons aged 65 years or older as generally,
cardiovascular sequelae become most apparent at advanced
e functiona
Cases, n Controls, n Cohort, n Follow-up, y Association with
genotype
90 68 c c Val/Val better
performanced
35 488 c c —
c c 1384 8 Val/Val worse
performancee
c c 525 c —
c c 523 3 Val/Val better
performance
c c 1540 8 —
—
c c 1384 8 —
c c 523 3 —
c c 1540 8 —
—
c c 1384 8 Val/Val worse
performancee
c c 523 3 —
c c 1540 8 —
—
c c 1384 8 —
c c 525 c —
iven in the supplementary file. Most studies investigated various CETP
brevity, data are reported only for the most common polymorphisms andognitiv
e, %
6b
ies is g
re. Forage (Lloyd-Jones et al., 2009). However, older homozygous
1851.e14 G.J. Izaks et al. / Neurobiology of Aging 33 (2012) 1851.e7–1851.e16I405V valine carriers still had better cognitive function after
adjusting for HDL cholesterol level and other cardiovascu-
lar risk factors. Besides, the CETP Taq1B B2/B2 genotype,
which relates to more pronounced differences in HDL cho-
lesterol compared with the I405V variation (Thompson et
al., 2008), was not predictive of cognitive function. There-
fore, it seems unlikely that the association of CETP I405V
genotype with cognitive function can be attributed in large
part to its effect on HDL cholesterol.
The role of CETP in plasma has been well characterized
but its role in the brain is largely unknown (Carter, 2007),
and to some extent controversial. CETP activity could be
detected in cerebrospinal fluid in 1 study (Albers et al.,
1992), but this was not confirmed in a more recent report
(Demeester et al., 2000). However, CETP may be expressed
Table 6
Systematic review of studies on the association of CETP genotype with d
Outcome/Reference CETP
polymorphism
Design Mean
age, y
Me
Alzheimer disease
Fidani et al.
(2004)
Taq1B Case-control 78, 84b 27,
Zhu et al. (2005) Taq1B Case-control 73, 88b 35,
Rodríguez et al.
(2006)
I405V Case-control 75, 80b 29,
Taq1B
C-629A
Arias-Vásquez et
al. (2007)
I405V Case-control 69 40
Chen et al.
(2008)
I405V Case-control 76, 78b 39,
Taq1B
Qureischie et al.
(2008)
I405V Case-control 72 32,
C-629A
Sanders et al.
(2010)
I405V Cohort 78c 49
Murphy et al.
(2012)
I405V Case-control 75, 76b 54
C-629A
Reynolds et al.
(2011)
I405V Cohort 78g 42
C-629A
Yu et al. (2012) I405V Cohort 78 30
Vascular dementia
Qureischie et al.
(2009)
I405V Case-control 71, 74b 43,
C-629A
Cholesteryl Ester Transfer Protein (CETP) genotype and cognitive functio
Key: Ile, isoleucine; Val, valine.
a A detailed description of the search strategy and selection of the studies
D442G (1 study), L269Q (1 study), and -1946 VNTR (1 study) were
b Reported separately for cases and controls.
c Not applicable.
d In APOE 4 carriers.
e In APOE 4 noncarriers.
f Ile/Val compared to Ile/Ile.
g Median age.
h Catholic nuns and priests.in astrocytes (Yamada et al., 1995). Until recently, astro-cytes were generally believed to have a mainly supportive
function for neurons in the central nervous system but new
evidence suggests that astrocytes also play a role in signal-
ing between brain cells and provide metabolic support for
neurons (Halassa and Haydon, 2010). Thus, an alternative
explanation for the association of CETP I405V genotype
with cognitive function might be sought in the role of
astrocytes in various brain regions.
There are some methodological aspects to our study that
need to be acknowledged. First, our findings could not be
validated in a replication cohort. This was largely due to the
use of the RFFT as outcome measure. The RFFT is a
sensitive cognitive test so that it was possible to measure
differences in cognitive function in relatively young persons
(Izaks et al., 2011), but it also is relatively new and yet not
riska
Cases, n Controls, n Cohort, n Incident
cases, n
Association with
genotype
102 97 c c —
163 154 c c —
286 315 c c —
—
A/A lower riskd
544 5644 c c Val/Val higher
risk
107 115 c c —
—
351 388 c c —
—
d d 523 40 Val/Val lower
risk
318 188 c c Val allele higher
riske,f
—
c c 2389 122 —
—
c c 1384 336 Val/Val higher
riskh
164 443 c c —
A/A higher riske
rsons aged 35 years or older.
n in the supplementary file. For brevity, data on the CETP polymorphisms
.ementia
n, %
28b
46b
32b
50b
47b
47b
n in pe
is give
omittedwidely known. As a consequence, an independent sample
1851.e15G.J. Izaks et al. / Neurobiology of Aging 33 (2012) 1851.e7–1851.e16with similar data on genotype and cognitive function was
not available. Second, the cross-sectional analysis may be
considered as a limitation because in general, it is not an
appropriate approach to investigate causal relationships.
Third, it should be mentioned that we used only 1 test of
cognitive function. Even so, the RFFT score is the outcome
of many different cognitive abilities. Moreover, In contrast
to many other tests, the RFFT does not seem to exhibit a
strong floor or ceiling effect as it has a wide range of scores.
Fourth, due to the design of the PREVEND study, the study
sample included a relatively high proportion of persons with
elevated albuminuria and hence, with increased cardiovas-
cular risk. However, similar results were found when the
analyses were repeated in a random sample from the general
population. Also, the association of CETP I405V genotype
with cognitive function appeared to be independent of car-
diovascular risk factors in multivariate analysis.
In conclusion, in this study, homozygous carriers of the
CETP I405V valine allele who were aged 65 years or older
had better cognitive function than heterozygous carriers and
noncarriers of comparable age. No differences were found
in persons aged 35 to 64 years.
Disclosure statement
The authors have no actual or potential conflicts of in-
terest.
The PREVEND study has been approved by the Medical
Ethical Committee (METc) of the University Medical Cen-
ter Groningen, Groningen, the Netherlands, and is con-
ducted in accordance with the guidelines of the Declaration
of Helsinki. Written informed consent was obtained from all
participants.
Acknowledgements
Hanneke Joosten, M.D., Department of Internal Medi-
cine, University Medical Center Groningen, Groningen, the
Netherlands, coordinated the analysis of the Ruff Figural
Fluency Test (RFFT) scores. Peter de Jonge, Ph.D., Depart-
ment of Psychiatry, Interdisciplinary Center of Psychiatric
Epidemiology, University Medical Center Groningen, Gro-
ningen, the Netherlands, advised on the statistical analysis.
We thank the PREVEND study group and the supporting
staff of PREVEND for their role in the logistics of the study
and the acquisition of the data used in this article.
This study was supported by the Dutch Alzheimer Foun-
dation (www.alzheimer-nederland.nl). The PREVEND
study in general was supported by the Dutch Kidney Foun-
dation (www.nierstichting.nl; Grant E.033). The sponsors of
the study had no role in the design or conduct of the study;
in the collection management, analysis, or interpretation of
the data; or in the preparation, review, or approval of the
manuscript.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.neurobiolaging.
2012.02.022.
References
Albers, J.J., Tollefson, J.H., Wolfbauer, G., Albright, R.E.J., 1992. Cho-
lesteryl ester transfer protein in human brain. Int. J. Clin. Lab. Res. 21,
264–266.
Arias-Vásquez, A., Isaacs, A., Aulchenko, Y.S., Hofman, A., Oostra, B.A.,
Breteler, M., van Duijn, C.M., 2007. The cholesteryl ester transfer
protein (CETP) gene and the risk of Alzheimer’s disease. Neurogenet-
ics 8, 189–193.
Barzilai, N., Atzmon, G., Derby, C.A., Bauman, J.M., Lipton, R.B., 2006.
A genotype of exceptional longevity is associated with preservation of
cognitive function. Neurology 67, 2170–2175.
Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., Tanzi, R.E., 2007.
Systematic meta-analyses of Alzheimer disease genetic association
studies: the AlzGene database. Nat. Genet. 39, 17–23.
Blaauwwiekel, E.E., Beusekamp, B.J., Sluiter, W.J., Hoogenberg, K., Dul-
laart, R.P., 1998. Apolipoprotein E genotype is a determinant of low-
density lipoprotein cholesterol and of its response to a low-cholesterol
diet in type 1 diabetic patients with elevated urinary albumin excretion.
Diabet. Med. 15, 1031–1035.
Borggreve, S.E., Hillege, H.L., Wolffenbuttel, B.H., de Jong, P.E., Bakker,
S.J., van der Steege, G., van Tol, A., Dullaart, R.P., PREVEND Study
Group, 2005. The effect of cholesteryl ester transfer protein -629C-A
promoter polymorphism on high-density lipoprotein cholesterol is de-
pendent on serum triglycerides. J. Clin. Endocrinol. Metab. 90, 4198–
4204.
Carter, C.J., 2007. Convergence of genes implicated in Alzheimer’s disease
on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and
atherosclerosis. Neurochem. Int. 50, 12–38.
Chen, D.W., Yang, J.F., Tang, Z., Dong, X.M., Feng, X.L., Yu, S., Chan,
P., 2008. Cholesteryl ester transfer protein polymorphism D442G as-
sociated with a potential decreased risk for Alzheimer’s disease as a
modifier for APOE epsilon4 in Chinese. Brain Res. 1187, 52–57.
Demeester, N., Castro, G., Desrumaux, C., De Geitere, C., Fruchart, J.C.,
Santens, P., Mulleners, E., Engelborghs, S., De Deyn, P.P., Vandeker-
ckhove, J., Rosseneu, M., Labeur, C., 2000. Characterization and func-
tional studies of lipoproteins, lipid transfer proteins, and lecithin:cho-
lesterol acyltransferase in CSF of normal individuals and patients with
Alzheimer’s disease. J. Lipid Res. 41, 963–974.
Fidani, L., Goulas, A., Crook, R., Petersen, R.C., Tangalos, E., Kotsis, A.,
Hardy, J., 2004. An association study of the cholesteryl ester transfer
protein TaqI B polymorphism with late onset Alzheimer’s disease.
Neurosci. Lett. 357, 152–154.
Gustafson, D., Rothenberg, E., Blennow, K., Steen, B., Skoog, I., 2003. An
18-year follow-up of overweight and risk of Alzheimer disease. Arch.
Intern. Med. 163, 1524–1528.
Halassa, M.M., Haydon, P.G., 2010. Integrated brain circuits: astrocytic
networks modulate neuronal activity and behavior. Annu. Rev. Physiol.
72, 335–355.
Hamilton, J.A., Deckelbaum, R.J., 2007. Crystal structure of CETP: new
hopes for raising HDL to decrease risk of cardiovascular disease? Nat.
Struct. Mol. Biol. 14, 95–97.
Izaks, G.J., Joosten, H., Koerts, J., Gansevoort, R.T., Slaets, J.P., 2011.
Reference data for the Ruff Figural Fluency Test stratified by age and
educational level. PLoS One 6, e17045.
Johnson, W., Harris, S.E., Collins, P., Starr, J.M., Whalley, L.J., Deary,
I.J., 2007. No association of CETP genotype with cognitive function or
age-related cognitive change. Neurosci. Lett. 420, 189–192.
1851.e16 G.J. Izaks et al. / Neurobiology of Aging 33 (2012) 1851.e7–1851.e16Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I.,
Winblad, B., Helkala, E.L., Tuomilehto, J., Soininen, H., Nissinen, A.,
2005. Obesity and vascular risk factors at midlife and the risk of
dementia and Alzheimer disease. Arch. Neurol. 62, 1556–1560.
Lambers Heerspink, H.J., Brantsma, A.H., de Zeeuw, D., Bakker, S.J., de
Jong, P.E., Gansevoort, R.T., PREVEND Study Group, 2008. Albu-
minuria assessed from first-morning-void urine samples versus 24-hour
urine collections as a predictor of cardiovascular morbidity and mor-
tality. Am. J. Epidemiol. 168, 897–905.
Prospective Studies Collaboration, Lewington, S., Whitlock, G., Clarke,
R., Sherliker, P., Emberson, J., Halsey, J., Qizilbash, N., Peto, R.,
Collins, R., 2007. Blood cholesterol and vascular mortality by age, sex,
and blood pressure: a meta-analysis of individual data from 61 pro-
spective studies with 55,000 vascular deaths. Lancet 370, 1829–1839.
Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson,
T.B., Flegal, K., Ford, E., Furie, K., Go, A., Greenlund, K., Haase, N.,
Hailpern, S., Ho, M., Howard, V., Kissela, B., Kittner, S., Lackland, D.,
Lisabeth, L., Marelli, A., McDermott, M., Meigs, J., Mozaffarian, D.,
Nichol, G., O’Donnell, C., Roger, V., Rosamond, W., Sacco, R., Sorlie,
P., Stafford, R., Steinberger, J., Thom, T., Wasserthiel-Smoller, S.,
Wong, N., Wylie-Rosett, J., Hong, Y., American Heart Association
Statistics Committee and Stroke Statistics Subcommittee, 2009. Heart
disease and stroke statistics–2009 update: a report from the American
Heart Association Statistics Committee and Stroke Statistics Subcom-
mittee. Circulation. 119, e21–e181.
Luchsinger, J.A., Reitz, C., Honig, L.S., Tang, M.X., Shea, S., Mayeux, R.,
2005. Aggregation of vascular risk factors and risk of incident Alzhei-
mer disease. Neurology 65, 545–551.
Mahmoodi, B.K., Gansevoort, R.T., Veeger, N.J., Matthews, A.G., Navis,
G., Hillege, H.L., van der Meer, J., Prevention of Renal and Vascular
End-stage Disease (PREVEND) Study Group, 2009. Microalbuminuria
and risk of venous thromboembolism. JAMA, 301, 1790–1797.
Monster, T.B., Janssen, W.M., de Jong, P.E., de Jong-van den Berg, L.T.,
PREVEND Study Group Prevention of REnal and Vascular ENT Stage
Disease, 2002. Pharmacy data in epidemiological studies: an easy to
obtain and reliable tool. Pharmacoepidemiol. Drug Saf. 11, 379–384.
Murphy, E.A., Roddey, J.C., McEvoy, L.K., Holland, D., Hagler, D.J.,
Dale, A.M., Brewer, J.B., Alzheimer’s Disease Neuroimaging Initia-
tive, 2012. CETP polymorphisms associate with brain structure, atro-
phy rate, and Alzheimer’s disease risk in an APOE-dependent manner.
Brain Imaging Behav. 6, 16–26.
Qureischie, H., Heun, R., Lütjohann, D., Popp, J., Jessen, F., Ledschbor-
Frahnert, C., Thiele, H., Maier, W., Hentschel, F., Kelemen, P., Kölsch,
H., 2008. CETP polymorphisms influence cholesterol metabolism but
not Alzheimer’s disease risk. Brain Res. 1232, 1–6.
Qureischie, H., Heun, R., Popp, J., Jessen, F., Maier, W., Schmitz, S.,
Hentschel, F., Kelemen, P., Kölsch, H., 2009. Association of CETP
polymorphisms with the risk of vascular dementia and white matter
lesions. J. Neural Transm. 116, 467–472.
Raffaitin, C., Féart, C., Le Goff, M., Amieva, H., Helmer, C., Akbaraly,
T.N., Tzourio, C., Gin, H., Barberger-Gateau, P., 2011. Metabolic
syndrome and cognitive decline in French elders: the Three-City Study.
Neurology 76, 518–525.
Reitz, C., Tang, M.X., Schupf, N., Manly, J.J., Mayeux, R., Luchsinger,
J.A., 2010. Association of higher levels of high-density lipoprotein
cholesterol in elderly individuals and lower risk of late-onset Alzhei-
mer disease. Arch. Neurol. 67, 1491–1497.
Reymer, P.W., Groenemeyer, B.E., van de Burg, R., Kastelein, J.J., 1995. Apoli-
poprotein E genotyping on agarose gels. Clin. Chem. 41, 1046–1047.Reynolds, C.A., Gatz, M., Pedersen, N.L., Prince, J.A., 2011. An assess-
ment of CETP sequence variation in relation to cognitive decline and
dementia risk. Int. J. Mol. Epidemiol. Genet. 2, 122–129.
Rodríguez, E., Mateo, I., Infante, J., Llorca, J., Berciano, J., Combarros, O.,
2006. Cholesteryl ester transfer protein (CETP) polymorphism modi-
fies the Alzheimer’s disease risk associated with APOE epsilon4 allele.
J. Neurol. 253, 181–185.
Ruff, R.M., 1996. Ruff Figural Fluency Test: Professional Manual. Psy-
chological Assessment Resources, Inc., Lutz, FL.
Ruff, R.M., Light, R.H., Evans, R.W., 1987. The Ruff Figural Fluency
Test: a normative study with adults. Dev. Neuropsychol. 3, 37–51.
Sanders, A.E., Wang, C., Katz, M., Derby, C.A., Barzilai, N., Ozelius, L.,
Lipton, R.B., 2010. Association of a functional polymorphism in the
cholesteryl ester transfer protein (CETP) gene with memory decline
and incidence of dementia. JAMA 303, 150–158.
Singh-Manoux, A., Gimeno, D., Kivimaki, M., Brunner, E., Marmot,
M.G., 2008. Low HDL cholesterol is a risk factor for deficit and decline
in memory in midlife: the Whitehall II study. Arterioscler. Thromb.
Vasc. Biol. 28, 1556–1562.
Thompson, A., Di Angelantonio, E., Sarwar, N., Erqou, S., Saleheen, D.,
Dullaart, R.P., Keavney, B., Ye, Z., Danesh, J., 2008. Association of
cholesteryl ester transfer protein genotypes with CETP mass and ac-
tivity, lipid levels, and coronary risk. JAMA 299, 2777–2788.
Twamley, E.W., Ropacki, S.A., Bondi, M.W., 2006. Neuropsychological
and neuroimaging changes in preclinical Alzheimer’s disease. J. Int.
Neuropsychol. Soc. 12, 707–735.
United Nations Educational, Scientific and Cultural Organization, 2006.
International Standard Classification of Education 1997. Re-Edition
2006. United Nations Educational, Scientific and Cultural Organiza-
tion, Montreal, Canada.
van den Berg, E., Kloppenborg, R.P., Kessels, R.P., Kappelle, L.J., Bies-
sels, G.J., 2009. Type 2 diabetes mellitus, hypertension, dyslipidemia
and obesity: A systematic comparison of their impact on cognition.
Biochim. Biophys. Acta 1792, 470–481.
van Exel, E., de Craen, A.J., Gussekloo, J., Houx, P., Bootsma-van der
Wiel, A., Macfarlane, P.W., Blauw, G.J., Westendorp, R.G., 2002.
Association between high-density lipoprotein and cognitive impair-
ment in the oldest old. Ann. Neurol. 51, 716–721.
Whitmer, R.A., Sidney, S., Selby, J., Johnston, S.C., Yaffe, K., 2005.
Midlife cardiovascular risk factors and risk of dementia in late life.
Neurology 64, 277–281.
World Health Organization, 1999. Definition, Diagnosis and Classification
of Diabetes Mellitus and Its Complications: Report of a WHO Con-
sultation. Part 1: Diagnosis and Classification of Diabetes Mellitus
(WHO/NCD/NCS/99.2). World Health Organization, Geneva, Switzer-
land.
Yamada, T., Kawata, M., Arai, H., Fukasawa, M., Inoue, K., Sato, T.,
1995. Astroglial localization of cholesteryl ester transfer protein in
normal and Alzheimer’s disease brain tissues. Acta Neuropathol. 90,
633–636.
Yu, L., Shulman, J.M., Chibnik, L., Leurgans, S., Schneider, J.A., De
Jager, P.L., Bennett, D.A., 2012. The CETP I405V polymorphism is
associated with an increased risk of Alzheimer’s disease. Aging Cell
11, 228–233.
Zhu, H., Gopalraj, R.K., Kelly, J.F., Bennett, D.A., Estus, S., 2005. Lack of
genetic association of cholesteryl ester transfer protein polymorphisms
with late onset Alzheimer’s disease. Neurosci. Lett. 381, 36–41.
